Cancer Vaccines Are Coming for Colorectal Cancer
Emerging vaccine therapies—both off‑the‑shelf and personalized—show promise for preventing colorectal cancer recurrence after surgery.
This blog summarizes recent vaccine developments for colorectal cancer, describing two main strategies—off‑the‑shelf and personalized neoantigen vaccines—alongside early‑phase clinical trial results that suggest potential for reducing recurrence.
Colorectal cancer often recurs after surgery, and current therapies have limited efficacy in preventing relapse, especially in microsatellite‑stable tumors. Vaccines that can stimulate immune clearance of residual disease could improve long‑term outcomes.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics